Avidity biosciences, inc. announces pricing of upsized public offering of common stock

San diego , dec. 15, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share. all of the shares to be sold in the offering are to be sold by avidity.
RNA Ratings Summary
RNA Quant Ranking